Close Menu

NEW YORK (GenomeWeb) — Singapore-based Lucence Diagnostics and NovogeneAIT Genomics Singapore announced today that they have partnered to develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.

According to the partners, the tests will be designed to analyze the genetics of cancer tissue to help personalize a patient's treatment regimen and will focus on cancers prevalent in Asia. Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.